Stay updated on XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Sign up to get notified when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.

Latest updates to the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant updates regarding a clinical study on XMT-1592, specifically changing the focus from a Phase 1b trial to an open-label, dose escalation study targeting patients with platinum-resistant ovarian cancer and non-squamous NSCLC. Key details about the study's design, including the maximum tolerated dose (MTD) confirmation process and the inclusion of collaborators, have been clarified.SummaryDifference34%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.